News
Current News
- NEW Anti-Gliadin (Modified Gliadin Peptide) EIA28 August 2008
- First myeloma kidney patient recruited onto EuLITE clinical trial09 June 2008
- Biennial 2008 - Serum Free Light Chain Symposium14 May 2008
- New Infectious Disease ELISA assays21 April 2008
- New Cystatin C assay for Roche Modular P18 March 2008
- Independent Review discusses Value of Serum Free Light Chain Assays11 February 2008
- Serum FLC ratio can help assess risk in patients with Smouldering Multiple Myeloma24 January 2008
- Serum free light chain assay recommended in initial investigation of myeloma19 October 2007
- New Hib (Haemophilus influenzae type b) Antibody Avidity test03 September 2007
28 August 2008
NEW Anti-Gliadin (Modified Gliadin Peptide) EIA
These 
assays are highly sensitive and specific for the measurement of human serum IgG and IgA antibodies against a modified gliadin peptide (MGP), as an aid in the diagnosis and monitoring of coeliac disease.
- More sensitive and specific than traditional assays that use a gliadin extract antigen preparation
- All assays can be used for screening or semi quantitative measurement of antibodies
- IgG, IgA or Combi kit formats available
- Validated protocols for DSX and DS2 automated systems
More information on all BINDAZYME autoimmune EIA or Contact us.
.jpg)